1.25Open1.25Pre Close0 Volume2 Open Interest35.00Strike Price0.00Turnover108.48%IV21.08%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry1.25Extrinsic Value100Contract SizeAmericanOptions Type0.3046Delta0.0482Gamma23.95Leverage Ratio-0.0713Theta0.0039Rho7.30Eff Leverage0.0235Vega
Spyre Therapeutics Stock Discussion
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average(.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index(.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index(.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks(DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
No comment yet